#Ocrelizumab – How Ocrelizumab Works

news-33

Ocrelizumab, an anti-CD20 monoclonal antibody, targets mature B-cells. Almost 95% of the B-cell population has these antigenic epitopes after maturation and does not shed them, which is what makes it a potent marker for therapeutic purposes (cancer being a very common area of interest in this regard).

Read more about Ocrelizumab here: http://bit.ly/1JUBLqj

Average Rating
0 out of 5 stars. 0 votes.
My Rating:

7 comments

  1. LYNNE HEAL says:

    This drug is not good at all please do all the research on as many have died after taking this one . PLEASE BE CAREFUL

  2. LYNNE HEAL says:

    Also note that MS societys are also promoted this drug along with many more too. Billions has been made from MS patients who have all been exploted for financial gains

  3. LYNNE HEAL says:

    EXPLOITED excuse my spellings . Lots of are all being exploited with MS because they all know many are bedridden and unable to use a computer thats how sick it all is

  4. Jill says:

    I have been taking ocrelizumab for 5 years with no side effects and my ms stopped progressing after 6 months of treatment. The results have been amazing for me.

Leave a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

Share This